Experienced leadership uniquely positioned to deliver our vision
Our team brings decades of experience and cutting-edge knowledge to the forefront in discovering and developing leading-edge medicines. Collectively, we are dedicated to developing novel therapies with the potential to transform the lives of patients living with cancer.
Our Leadership
Board of Directors
Vlad Coric, MD
CEO, Biohaven Ltd.
John Childs, MBA
Chairman & CEO,
JW Childs Associates L.P.
Larry Feinberg, MBA
Managing Partner, Oracle Investment Management Inc.
Aleksander Rabodzey
Managing Director, Suvretta Capital Management
Brian Lestini, MD, PhD
Chief Executive Officer
Scientific Advisory Board
Manmeet Ahluwalia, MD, FACP, MBA
Chief of Solid Tumor Medical Oncology, Deputy Director and Chief Scientific Officer, Miami Cancer Institute
Daniel Cahill, MD, PhD
Professor, Neurosurgery & Oncology, Harvard Medical
Director of Neuro-Oncology, Massachusetts General Hospital
Moses Chao, PhD
Professor, NYU Langone Medical Center
Timothy Cloughsey, MD
Director, Neuro-Oncology Program at UCLA Medical; Professor of Neurology
George Demetri, MD
Professor, Harvard, Dana Farber; Director of Sarcoma Center
BOD & SAB, Blueprint Medicines
Lori Kunkel, MD
Former CMO & BOD, LoxoOncology; Former CMO, Pharmacyclics
BOD/SAB, Elevation, Rain, Maverick, Nurix, Curis
Michael Lim, MD
Chair of Neurosurgery at Stanford Medicine; former professor of neurosurgery & oncology, Johns Hopkins
David Reardon, MD
Former President of the Society for Neuro-Oncology
Director of Center for Neuro-Oncology, DFCI
John Sampson, MD, PhD, MBA, MHSc
Professor & former Chair of Neurosurgery, Duke University
Member, National Academy of Medicine
Dave Solit, MD
Geoffrey Beene Chair; Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Katherine Warren, MD
Clinical Director of Pediatric Neuro-Oncology, Boston Children’s/DFCI; former Head of Pediatric Neuro-Oncology Group, National Cancer Institute
